Spinifex had raised just over $60m in funding, including $45m in a Novo-backed series C round in April 2014.
Pharmaceutical firm Novartis agreed to acquire Australia-based drug developer Spinifex Pharmaceuticals today for $200m in a cash deal that will provide pharmaceutical company Novo with an exit.
Spinifex is developing drugs to treat chronic pain, and its lead product candidate is EMA401, an oral treatment for chronic pain, and in particular neuropathic pain, that would work without any central nervous system-based side effects.
The company raised $45m in April 2014 from Novo in a series C round that also…
